• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Zimmer Biomet Holdings Inc.

    11/20/24 4:35:57 PM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    8-A12B 1 d870491d8a12b.htm 8-A12B 8-A12B

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-A

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR 12(g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   13-4151777
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
    345 East Main Street  
    Warsaw, Indiana   46580
    (Address of principal executive offices)   (Zip Code)

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    to be so registered

     

    Name of each exchange on which

    each class is to be registered

    3.518% Notes due 2032   New York Stock Exchange

     

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box: ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box: ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box: ☐

    Securities Act registration statement or Regulation A offering statement file number to which this form relates:

    333-263051

    Securities to be registered pursuant to Section 12(g) of the Act:

    None

     

     

     


    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Zimmer Biomet Holdings, Inc., a Delaware corporation (the “Company”), has filed with the U.S. Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, a prospectus supplement dated November 13, 2024 (the “Prospectus Supplement”) to a Prospectus dated February 25, 2022 (the “Prospectus”), contained in the Company’s effective Registration Statement on Form S-3 (Registration No. 333-263051), which Registration Statement was filed with the Commission on February 25, 2022, relating to the securities to be registered hereunder. The Company incorporates by reference the Prospectus and the Prospectus Supplement to the extent set forth below.

     

    Item 1.

    Description of Registrant’s Securities to be Registered.

    The securities to be registered hereunder are the Company’s €700,000,000 3.518% Notes due 2032. The information required by this item is incorporated by reference to the information contained in the sections captioned “Description of the Notes” in the Prospectus Supplement and “Description of Debt Securities We May Offer” in the Prospectus.

     

    Item 2.

    Exhibits.

     

    4.1

    Indenture, dated as of November 17, 2009, between Zimmer Holdings, Inc. (now known as Zimmer Biomet Holdings, Inc.) and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed December 13, 2016).

     

    4.2

    Eleventh Supplemental Indenture, dated as of November 20, 2024, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed November 20, 2024).

     

    4.3

    Agency Agreement, dated as of November 20, 2024, by and among Zimmer Biomet Holdings, Inc., as issuer, U.S. Bank Europe DAC, UK Branch, as paying agent, U.S. Bank Trust Company, National Association, as registrar and transfer agent, and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed November 20, 2024).

     

    4.4

    Form of 3.518% Notes due 2032 (included in Exhibit 4.2).


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

    Date: November 20, 2024

     

    ZIMMER BIOMET HOLDINGS, INC.
    By:  

    /s/ Chad F. Phipps

    Name:   Chad F. Phipps
    Title:   Senior Vice President, General Counsel and Secretary
    Get the next $ZBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    1/9/2026$93.00Neutral → Sell
    Goldman
    1/6/2026Outperform → Mkt Perform
    Raymond James
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    12/16/2025$100.00Outperform → Neutral
    Robert W. Baird
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2025 Financial Results

    WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be webcast on Tuesday, February 10, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to d

    1/15/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference

    WARSAW, Ind., Dec. 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer BiometZimmer Biomet is a global medic

    12/22/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group President, Asia Pacific Yi Sang sold $96,490 worth of shares (1,000 units at $96.49), decreasing direct ownership by 5% to 17,670 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/17/26 4:07:06 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Shapiro Louis

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    1/5/26 4:08:38 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Higgins Arthur J

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    1/5/26 4:07:45 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/17/26 5:08:28 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    2/10/26 6:30:26 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 8-K filed by Zimmer Biomet Holdings Inc.

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    1/12/26 9:00:34 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet downgraded by Goldman with a new price target

    Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00

    1/9/26 8:52:52 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet downgraded by Raymond James

    Raymond James downgraded Zimmer Biomet from Outperform to Mkt Perform

    1/6/26 8:47:57 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Zimmer Biomet from In-line to Outperform and set a new price target of $210.00

    1/5/26 8:38:11 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

    WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

    3/6/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2025 Financial Results

    WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be webcast on Tuesday, February 10, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to d

    1/15/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2025

    WARSAW, Ind., Dec. 17, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2025. The cash dividend of $0.24 per share is payable on or about January 30, 2026 to stockholders of record as of the close of business on December 30, 2025. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We

    12/17/25 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care